OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Claire is currently a Partner in the Life Science team at Oxford Science Enterprises, an investment company that creates transformational businesses via a unique partnership with the University of Oxford, UK, the world’s #1 research university. Her focus is building and investing in novel therapeutics and therapeutic platforms across diverse therapy areas and modalities. She currently supports a number of OSE’s emerging companies incl. T-Cypher Bio, Nucleome, Alveogene and Orfonyx. Claire has spent the majority of her career in the global BioPharmaceutical industry at UCB Group, Sanofi-Genzyme and AstraZeneca where she worked in a variety of roles covering R&D strategy, licensing and corporate VC.
